

Time:3 Hours

Marks:75

Q. I Choose appropriate option for following multiple choice-based questions and write down the correct answer 20

- 1 Which of the following is an acute toxicity symptom?
 - a Carcinogenesis
 - b Hypothermia
 - c Mutation
 - d Hepatotoxicity

- 2 Dose that produces side effects in 10% of exposed, relative to control is called
 - a LD50
 - b LED10
 - c LOAEL
 - d NOAEL

- 3 Toxicity studies which are carried out throughout the total lifespan of the test animal are
 - a Acute toxicity studies
 - b Subacute toxicity studies
 - c Sub-chronic toxicity studies
 - d Chronic toxicity studies

- 4 A quality system concerned with non-clinical health and environmental safety studies is
 - a Good Laboratory Practice
 - b Good Clinical Practice
 - c Good Health Practice
 - d Good Safety Practice

- 5 A study that allows selection of the appropriate starting concentration for the main study is
 - a Preclinical study
 - b Limit test
 - c Dose selection study
 - d Sighting study

- 6 Which of the following option conveys the purpose of ICH S5(R2) guidelines on Reproductive toxicology?
 - a They are non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals
 - b They detect reproductive toxicity for medicinal products including toxic effects on male fertility
 - c They detect preclinical safety evaluation of biotechnology - derived pharmaceuticals
 - d They guide for assessing systemic exposure in toxicology studies

- 7 United States Environment Protection Agency Test Guidelines for Pesticides are issued as per which of the following Act?
- a Federal Insecticide, Fungicide and Rodenticide Act (FIFRA)
 - b Prevention of Cruelty to Animals Act
 - c Wildlife Protection Act
 - d Federal Pollution Control Act
- 8 The OECD Guideline entitled " Acute Oral Toxicity- Up & Down Procedure" aims to estimate a
- a Dose Progression Factor
 - b Volume of Distribution
 - c Bioaccumulation Potential
 - d Median Lethal Dose -LD 50
- 9 Which of following statement is incorrect about the data derived from toxicological studies:
- a they provide pharmacokinetic data that can be used to define the test measurement intervals
 - b they provide acute toxicity data that can be used to select the appropriate high dose
 - c they provide toxicology/pathology findings that can be used to help define the mechanism of the functional changes measured in safety pharmacology studies.
 - d they provide clinical data on the proper usage of drugs.
- 10 General principles of teratology include all the following except:
- a Teratogenic agents act via specific pathways
 - b The final manifestations of abnormal development are death, malformation, growth retardation and functional disorder.
 - c Susceptibility of the conceptus to teratogenic agents varies with the developmental stage at the time of exposure.
 - d Recommendations related to contraception and pregnancy testing in clinical trials.
- 11 The ICH Guideline entitled "Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility" is:
- a S-5 R (2)
 - b E-3 R (1)
 - c S-11 R (2)
 - d E-15 R (2)
- 12 The disadvantage of Rat as an experimental animal for Reproductive Toxicity Study is:
- a Unsuitable for Dopamine Agonists
 - b Lack of Kinetic and Toxicity Data
 - c Susceptibility to Antibiotics
 - d Long Foetal Period

- 13 Studies that evaluate adverse pharmacodynamic effects of a substance observed in clinical studies are:
- a Cell Based Assays
 - b Safety Pharmacology Studies
 - c Toxicokinetic Studies
 - d Preclinical Efficacy Studies
- 14 Safety pharmacology studies
- a Define the pharmacokinetics of the drugs
 - b define the dose-response relationship of the adverse effect observed
 - c Are done to determine the pharmacodynamics of the drug
 - d They determine the acute toxicity of the drug
- 15 Before a potential pharmaceutical compound can be given to humans:
- a An NDA must be filed with the FDA
 - b Acute Toxicity studies on 4 species must be conducted
 - c A 2-year Dog Carcinogenicity study must be completed
 - d An IND must be filled with the FDA
- 16 Safety Pharmacology Studies are not necessary for
- a Pharmaceuticals for Dermal Application
 - b Parenterals
 - c Sublingual products
 - d Oral suspensions
- 17 Which one of the following is a Toxicokinetic Parameter ?
- a Volume of Distribution
 - b Dose Response Curve
 - c Receptor Binding of Toxicant
 - d Median Lethal Dose
- 18 Drugs which are extensively metabolized like phenytoin exhibit
- a Zero order kinetics
 - b First order kinetics
 - c Linear pharmacokinetics
 - d Nonlinear pharmacokinetics
- 19 Which one of the following is an alternative to In-vivo Animal Toxicity Studies?
- a Strychnine Induced Convulsions in Rats
 - b Carcinogenicity Study in Mice
 - c Physiological Based Toxicokinetic Modelling
 - d Histamine Bioassay using Guinea Pig Trachea

- 20 Which of the following represents application of Toxicokinetic studies?
- a identification of multiple types of calcium channels
 - b investigation of a wider angle of electrophysiological cell properties.
 - c measurement of cell membrane conductance.
 - d drug development stages especially in preclinical stage.

Q.II Answer (any TWO) from the following:

20

- a Write a short note on Acute Dermal Toxicity and Inhalational studies as per OECD guideline.
- b Give an account of Female Reproductive Studies (seg I and seg III)
- c Write a descriptive note on safety pharmacology.

Q.III Answer (any SEVEN) from the following:

35

- a Enlist various OECD Guideline for Oral Toxicity Studies. Describe Any One OECD Test Guideline for Oral Toxicity Studies.
- b Write a short note on EPA studies.
- c Write a note on skin sensitization studies.
- d What do you mean by Test item? Discuss the characterization for specific test item.
- e Write a short note on the following:
 - (a) Ames test
 - (b) In vivo micronucleus assay
- f Give an account of Male Reproductive Toxicity Studies.
- g Write a short note on IND studies.
- h Write a note on Importance and Application of Toxicokinetic Studies.
- i Give an account of toxicokinetic evaluation in preclinical studies.
